Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 752 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Glaucoma Eye Clear all

Conditions: Glaucoma
Interventions: Restasis, Endura (artificial tears); Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Open Angle Glaucoma
Interventions: Nasal 180° Selective Laser Trabeculoplasty (SLT), Inferior 180° Selective Laser Trabeculoplasty (SLT); Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
Interventions: Hydrus Microstent, iStent Trabecular Micro Bypass; Device
Lead sponsor: Ivantis, Inc.; Industry
Eligibility: 45 Years to 84 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Irvine, California

Conditions: Optic Neuropathy, Glaucoma
Interventions: Hyperbaric Oxygen, Sham Hyperbaric Oxygen; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy; Device · Drug
Lead sponsor: Aeon Astron Europe B.V.; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Rogers, Arkansas • Chicago, Illinois • Newark, New Jersey + 4 more

Conditions: Glaucoma, Vision Disorder
Interventions: Virtual Reality Stimulation; Device
Lead sponsor: Stanford University; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Glaucoma, Suspect
Interventions: Pattern Electroretinogram; Diagnostic Test
Lead sponsor: Jorvec Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Retinal Disease, Glaucoma
Interventions: Optos P200TE, Predicate Device; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 22 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Glaucoma
Interventions: Trabeculectomy, Ex-PRESS mini shunt; Procedure · Device
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 7
States / cities: San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more

Conditions: Glaucoma
Interventions: Sterile commercially available bandage contact lens, Medical grade silicone of a thickness >100 µm, Medical grade silicone of a thickness <100 µm with blur tint, Standard tip in conjunction with a topical anesthetic; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial); Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: App; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 32
States / cities: Chandler, Arizona • Glendale, California • Mission Hills, California + 28 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Courtney Frazier Swaney; Other
Eligibility: 40 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cataract
Interventions: Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion; Drug
Lead sponsor: Cathleen McCabe MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Glaucoma, Primary Open Angle
Interventions: NT-501 CNTF Implant; Drug
Lead sponsor: Jeffrey L Goldberg; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: bimatoprost 0.03% eye drops, latanoprost 0.005% eye drops; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Open Angle Glaucoma
Interventions: Suprachoroidal Dissection Instrument (SDI); Device
Lead sponsor: iScience Interventional Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions: Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Glaucoma, Suspect
Interventions: Standard GAT, Fixed force GAT, Upright applanating prototype, Supine Applanating Prototype; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

Hyperbaric Oxygen Therapy for Optic Neuropathies

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Virtual Reality for Enhancement of Vision

CLAD Deconvolved PERG Responses in Glaucoma Patients

Optos P200TE Agreement and Precision Study

Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma

Tolerability of an Anesthesia-free Tonometer Tip

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

An App-based Instructional Platform to Improve Eye Drop Recall

DE-117 Spectrum 5 Study

Aqueous Outflow Facility Changes With Posture

Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Surgical Treatment of Refractory Open Angle Glaucoma

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Travoprost Five Day Posology Study

Automated Applanation Tonometry